Several months after Retrophin announced that it would divest several of its pipeline products, including Syntocinon intranasal oxytocin and intranasal ketamine, to Turing Pharmaceuticals, the latter company has officially announced its launch. Turing Pharmaceuticals is headed by Martin Shkreli, who left Retrophin suddenly after reports of “stock trading irregularities.”
Shkreli commented, “”Our goal is to build a diverse portfolio and pipeline of therapies that can make a significant difference to patients. We are creating a strong, experienced team at Turing with a solid track record of success to execute on our objectives.”
According to Turing, the company is “developing its new intranasal formulation of ketamine for a variety of psychiatric indications. The company is making significant investments in a novel delivery mechanism and other innovations to develop ketamine for the treatment of several serious psychiatric conditions for patients who currently have limited treatment options, and expects to commence clinical trials in the coming year.”
The company’s website indicates that intranasal ketamine is currently in Phase 2 development for the treatment of suicidal ideation.
Read the Turing Pharmaceuticals press release.
